Management

Michael Boyce-Jacino, Ph.D., President and CEO

Michael Boyce-Jacino has served as president and CEO since 2004. He has more than 20 years of senior management and scientific experience in the development and commercialization of innovative products for genetic analysis. Prior to joining BioNanomatrix, Dr. Boyce-Jacino served as vice president and director of the global genomics research business for Beckman Coulter. Previously, he served as chief scientific officer at Orchid BioSciences, where he helped pioneer the development of innovative technologies for the genetic analysis of single nucleotide polymorphisms, or SNPs. Earlier in his career, Dr. Boyce-Jacino was president of genetic analysis company Molecular Tool, Inc., later acquired by Orchid. Dr. Boyce-Jacino received a B.S. degree from the University of Wisconsin-Madison and a Ph.D. from the University of Minnesota. He holds numerous patents for his work in genotyping technologies.

Han Cao, Ph.D., Founder and Chief Scientific Officer

Han Cao founded BioNanomatrix in 2003 as a spinout of a Princeton University Project funded by Defense Advanced Research Project Agency (DARPA). Dr. Cao is a co-inventor of the company’s core single-molecule nanoscale whole genome analysis technology. His diverse scientific experience includes molecular biology, microarray and genomics technology development, stem cell, and micro and nanofluidics design and fabrication. He is currently leading multiple federal government funded projects, and a frequently invited speaker, lecturer and panelist at national and international biotech and nanotech events. Dr. Cao received his BS degree from University of Science and Technology of China (USTC) and a PH.D. in Molecular Biology from University of Delaware.

Lorraine LePresti, CPA, MBA, VP & Chief Financial Officer

Lorraine LoPresti joined BioNanomatrix in 2007.  She has more than 20 years of experience in accounting and finance, serving in positions of increasing responsibility at public accounting firms and at several Fortune 500 corporations.  Prior to joining BioNanomatrix, Ms. LoPresti was director, financial services for the Science Center of Philadelphia, where she also served as CFO for a number of early stage biotechnology companies. Ms. LoPresti was founder and president of Gracemark Solutions, Inc., a financial consulting practice.   She received a B.S. in accountancy from Villanova University and an MBA from Rutgers University.

Board of Directors

Michael Boyce-Jacino, Ph.D., President and CEO

Michael Boyce-Jacino has served as president and CEO since 2004. He has more than 20 years of senior management and scientific experience in the development and commercialization of innovative products for genetic analysis. Prior to joining BioNanomatrix, Dr. Boyce-Jacino served as vice president and director of the global genomics research business for Beckman Coulter. Previously, he served as chief scientific officer at Orchid BioSciences, where he helped pioneer the development of innovative technologies for the genetic analysis of single nucleotide polymorphisms, or SNPs. Earlier in his career, Dr. Boyce-Jacino was president of genetic analysis company Molecular Tool, Inc., later acquired by Orchid. Dr. Boyce-Jacino received a B.S. degree from the University of Wisconsin-Madison and a Ph.D. from the University of Minnesota. He holds numerous patents for his work in genotyping technologies.

Edward L. Erickson

Mr. Erickson is a well-known industry executive with extensive experience in the biotechnology industry.  Currently a consultant to life science and venture capital firms, he serves on a number of private and public company boards. Previously, Mr. Erickson served as president, CEO and/or a director of over a dozen medical products firms, including Barrier Therapeutics, Cellatope Corporation, Cholestech, DepoTech, Immunicon and Megabios.  Four of these firms successfully completed IPOs during his tenure.  Earlier in his career he held senior management positions with Amersham International and Serono.  Mr. Erickson earned B.S. and M.S. degrees from the Illinois Institute of Technology and an MBA from Harvard Business School.

Tracy Warren

Ms. Warren is a general partner at Battelle Ventures and Innovation Valley Partners, where she focuses primarily on investments in healthcare, life sciences and emerging energy technologies.  She led the firm’s healthcare investments in BioNanomatrix, Endovalve and NuPathe, and non-healthcare investments in Metatomix, SmartSynch and Superprotonic.  Prior to Battelle Ventures, Ms. Warren was an associate at a predecessor venture capital fund.  Previously, she worked as an analyst in Healthcare Mergers and Acquisitions and as an associate in Corporate Finance at SG Cowen Securities, focusing on companies in the medical device and healthcare information technology fields.  Ms. Warren received a B.S. from New York University’s Stern School of Business and an MBA from Columbia Business School.

Scientific Advisory Board

Norm Dovichi, Ph.D., is an Endowed Professor of Analytical Chemistry at the University of Washington in Seattle. His group developed one of the most critical technical components in high throughput DNA sequencer responsible for the fast completion of the vast majority data in the Human Genome Project (HGP). He was named one of the two “Unsung Heros” behind the HGP and has won numerous prestigious awards. Dr. Dovichi’s current research focuses on the development of systems for the analysis of the protein content of single cancer cells. He is a key member of the Nanotechnology Institute at University Washington.

Paul R. Selvin, Ph.D. is a professor of physics, biophysics and affiliated professor of the cell and developmental biology departments at the University of Illinois, Urbana-Champaign. He won the Biophysical Society’s top award for Outstanding Young Investigator in 2004, the 2006 Raymond and Beverly Sakmann Award from Tel Aviv University for the most outstanding biophysics advance and is a University Scholar. Dr. Selvin invented a nanoimaging imaging technique called FIONA, or Fluorescence Imaging with One Nanometer Accuracy.  Professor Selvin received a B.S. from the University of Michigan in 1983 and a Ph.D. from the University of California, Berkeley.  He was a postdoctoral fellow at the Lawrence Berkeley National Laboratory at the University of California, Berkeley.  Professor Selvin has authored over 70 publications and holds five patents.

Lawrence J. DeLucas, O.D., Ph.D., is a former NASA astronaut and a Professor in the School of Optometry, the Director of the Comprehensive Cancer Center X-ray Core Facility, and the Director of the Center for Biophysical Sciences and Engineering (CBSE) at the University of Alabama at Birmingham (UAB). As a NIH Center for Structural Genomics, and a member of the Southeast Regional Collaborative Access Team (SERCAT), a consortium of 22 universities in the southeastern U.S., CBSE is one of the largest X-ray crystallography facilities in the world. He flew as a Space Shuttle Payload Specialist on the United States Microgravity Laboratory-1, participating in thirty-one different scientific projects in space. Dr. DeLucas is a renowned expert in protein crystallography, proteomics and structure-based drug design. He was named as one of the scientists who could shape the 21st century in an article published by London Times titled “The Brains Behind the 21st Century.”